Lillian Smyth

9PUBLICATIONS
98CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Health and ecological risk assessmentPredictive and prognostic markersMetabolomic chemistryMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.

Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton

|Sep 06, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn

|Feb 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.

Michele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker

|Jun 19, 2021
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.

A Rose Brannon, Gowtham Jayakumaran, Monica Diosdado

|Apr 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.

Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam

|Apr 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.

Lillian M Smyth, Kenji Tamura, Mafalda Oliveira

Pageof 2

Frequent Collaborators

4 joint publications

Sarat Chandarlapaty

3 joint publications

Monica Arnedos

2 joint publications

Mia Levy

2 joint publications

Udai Banerji